標(biāo)題: Titlebook: Drugs for HER-2-positive Breast Cancer; Maria Sibilia,Christoph C. Zielinski,Thomas W. Gru Book 2011 Springer Basel AG 2011 HER-2-positive [打印本頁(yè)] 作者: energy 時(shí)間: 2025-3-21 18:34
書(shū)目名稱(chēng)Drugs for HER-2-positive Breast Cancer影響因子(影響力)
書(shū)目名稱(chēng)Drugs for HER-2-positive Breast Cancer影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Drugs for HER-2-positive Breast Cancer網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Drugs for HER-2-positive Breast Cancer網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Drugs for HER-2-positive Breast Cancer被引頻次
書(shū)目名稱(chēng)Drugs for HER-2-positive Breast Cancer被引頻次學(xué)科排名
書(shū)目名稱(chēng)Drugs for HER-2-positive Breast Cancer年度引用
書(shū)目名稱(chēng)Drugs for HER-2-positive Breast Cancer年度引用學(xué)科排名
書(shū)目名稱(chēng)Drugs for HER-2-positive Breast Cancer讀者反饋
書(shū)目名稱(chēng)Drugs for HER-2-positive Breast Cancer讀者反饋學(xué)科排名
作者: Agnosia 時(shí)間: 2025-3-21 21:20
2296-6056 le source of information for researchers and clinicians from.Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in m作者: lacrimal-gland 時(shí)間: 2025-3-22 02:27
https://doi.org/10.1007/978-3-0346-0094-1HER-2-positive Breast Cancer; Pertuzumab; Second Generation targeted Therapies; Trastuzumab; antibodies作者: 手段 時(shí)間: 2025-3-22 07:00
978-3-0348-0318-2Springer Basel AG 2011作者: 間諜活動(dòng) 時(shí)間: 2025-3-22 08:50
Drugs for HER-2-positive Breast Cancer978-3-0346-0094-1Series ISSN 2296-6056 Series E-ISSN 2296-6064 作者: 墊子 時(shí)間: 2025-3-22 14:52 作者: 墊子 時(shí)間: 2025-3-22 19:24
Milestones in Drug Therapyhttp://image.papertrans.cn/e/image/283218.jpg作者: 摻假 時(shí)間: 2025-3-22 23:25
Book 2011ch as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting..作者: Pseudoephedrine 時(shí)間: 2025-3-23 05:06 作者: dainty 時(shí)間: 2025-3-23 06:05
Trastuzumab as Adjuvant Treatment for Early Stage HER-2-positive Breast Cancer,作者: 過(guò)度 時(shí)間: 2025-3-23 10:51 作者: Presbycusis 時(shí)間: 2025-3-23 16:03
Beyond Trastuzumab: Second-Generation Targeted Therapies for HER-2-positive Breast Cancer,作者: 消耗 時(shí)間: 2025-3-23 21:09 作者: 我要威脅 時(shí)間: 2025-3-23 23:59
第4樓作者: 注射器 時(shí)間: 2025-3-24 05:57
第4樓作者: 自由職業(yè)者 時(shí)間: 2025-3-24 08:14
第4樓作者: 誹謗 時(shí)間: 2025-3-24 13:01
5樓作者: 夾死提手勢(shì) 時(shí)間: 2025-3-24 18:30
5樓作者: radiograph 時(shí)間: 2025-3-24 19:19
5樓作者: 感染 時(shí)間: 2025-3-25 01:54
5樓作者: 符合國(guó)情 時(shí)間: 2025-3-25 04:40
6樓作者: arterioles 時(shí)間: 2025-3-25 07:44
6樓作者: Instrumental 時(shí)間: 2025-3-25 13:26
6樓作者: Demulcent 時(shí)間: 2025-3-25 19:09
7樓作者: 增減字母法 時(shí)間: 2025-3-25 20:12
7樓作者: 魅力 時(shí)間: 2025-3-26 01:58
7樓作者: Ganglion 時(shí)間: 2025-3-26 05:48
7樓作者: 加強(qiáng)防衛(wèi) 時(shí)間: 2025-3-26 09:15
8樓作者: 坦白 時(shí)間: 2025-3-26 15:13
8樓作者: ascend 時(shí)間: 2025-3-26 20:36
8樓作者: 煩人 時(shí)間: 2025-3-26 21:59
8樓作者: 多山 時(shí)間: 2025-3-27 03:08
9樓作者: 撫育 時(shí)間: 2025-3-27 07:23
9樓作者: 臨時(shí)抱佛腳 時(shí)間: 2025-3-27 09:42
9樓作者: HOWL 時(shí)間: 2025-3-27 14:08
9樓作者: 用手捏 時(shí)間: 2025-3-27 20:34
10樓作者: faculty 時(shí)間: 2025-3-28 00:25
10樓作者: febrile 時(shí)間: 2025-3-28 04:05
10樓作者: commute 時(shí)間: 2025-3-28 09:31
10樓
